TP53 and ovarian cancer: Nevertheless, our analyses of somatic alterations suggest that models where the ovarian cancer or metastatic lesions seed the FT tumors20, 21 (including STICs or p53 signatures) are infrequent and unlikely to be the source of most FT lesions.